title: Cyclodextrins as Emerging Therapeutic Tools in the Treatment of Cholesterol-Associated Vascular and Neurodegenerative Diseases.
abstract: Cardiovascular diseases, like atherosclerosis, and neurodegenerative diseases affecting the central nervous system (CNS) are closely linked to alterations of cholesterol metabolism. Therefore, innovative pharmacological approaches aiming at counteracting cholesterol imbalance display promising therapeutic potential. However, these approaches need to take into account the existence of biological barriers such as intestinal and blood-brain barriers which participate in the organ homeostasis and are major defense systems against xenobiotics. Interest in cyclodextrins (CDs) as medicinal agents has increased continuously based on their ability to actively extract lipids from cell membranes and to provide suitable carrier system for drug delivery. Many novel CD derivatives are constantly generated with the objective to improve CD bioavailability, biocompatibility and therapeutic outcomes. Newly designed drug formulation complexes incorporating CDs as drug carriers have demonstrated better efficiency in treating cardiovascular and neurodegenerative diseases. CD-based therapies as cholesterol-sequestrating agent have recently demonstrated promising advances with KLEPTOSE®CRYSMEB in atherosclerosis as well as with the 2-hydroxypropyl-β-cyclodextrin (HPβCD) in clinical trials for Niemann-Pick type C disease. Based on this success, many investigations evaluating the therapeutical beneficial of CDs in Alzheimer's, Parkinson's and Huntington's diseases are currently on-going.
authors.affiliation: Laboratoire de la barrière hémato-encéphalique (LBHE), University Artois, EA 2465, Lens, F-62300, France. c_coisne@yahoo.fr.
authors.forename: Caroline
authors.initials: C
authors.lastname: Coisne
authors.affiliation: Unité de Catalyse et de Chimie du Solide (UCCS), University Artois, CNRS, UMR 8181, Lens, F-62300, France. sebastien.tilloy@univ-artois.fr.
authors.forename: Sébastien
authors.initials: S
authors.lastname: Tilloy
authors.affiliation: Unité de Catalyse et de Chimie du Solide (UCCS), University Artois, CNRS, UMR 8181, Lens, F-62300, France. eric.monflier@univ-artois.fr.
authors.forename: Eric
authors.initials: E
authors.lastname: Monflier
authors.affiliation: ROQUETTE, Nutrition & Health R & D, 62136 Lestrem, France. DANIEL.WILS@roquette.com.
authors.forename: Daniel
authors.initials: D
authors.lastname: Wils
authors.affiliation: Laboratoire de la barrière hémato-encéphalique (LBHE), University Artois, EA 2465, Lens, F-62300, France. laurence.tilloy@univ-artois.fr.
authors.forename: Laurence
authors.initials: L
authors.lastname: Fenart
authors.affiliation: Laboratoire de la barrière hémato-encéphalique (LBHE), University Artois, EA 2465, Lens, F-62300, France. fabien.gosselet@univ-artois.fr.
authors.forename: Fabien
authors.initials: F
authors.lastname: Gosselet
mesh_terms: D000818:Animals; D050197:Atherosclerosis / Q000188:drug therapy; D001812:Blood-Brain Barrier; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D002784:Cholesterol / Q000378:metabolism; D002986:Clinical Trials as Topic; D003505:Cyclodextrins / Q000737:chemistry*; D004195:Disease Models, Animal; D004337:Drug Carriers / Q000737:chemistry*; D006801:Humans; D050356:Lipid Metabolism; D019636:Neurodegenerative Diseases / Q000188:drug therapy*
chemical_list: D003505:Cyclodextrins; D004337:Drug Carriers; D002784:Cholesterol
keywords: Alzheimer’s disease (AD); HPβCD; KLEPTOSE® CRYSMEB; Niemann-Pick disease type C (NPC); atherosclerosis; blood-brain barrier (BBB); cholesterol; cyclodextrins; neurodegenerative diseases; vascular diseases